Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of INV-101 in Healthy Adults
NCT05844592Phase 1Completed
- Sponsor
- Innovo Therapeutics
- Start
- Apr 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zevaquenabant in ulcerative colitis (UC) (5 cohorts), sponsored by Innovo Therapeutics. Primary endpoint: Adverse Events at 2 weeks. Started Apr 2022; status: completed.
02
Drugs
zevaquenabant
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05844592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844592.